Cannabinoid type 1 receptor antagonists for smoking cessation
about
Psychosocial interventions for supporting women to stop smoking in pregnancyPharmacological interventions for smoking cessation: an overview and network meta-analysisNicotine-induced anxiety-like behavior in a rat model of the novelty-seeking phenotype is associated with long-lasting neuropeptidergic and neuroplastic adaptations in the amygdala: effects of the cannabinoid receptor 1 antagonist AM251The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence.Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humansWeight gain in smokers after quitting cigarettes: meta-analysis.Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and RelapsePlasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of SchizophreniaAn assessment of factors associated with quality of randomized controlled trials for smoking cessation.Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach.The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel MonkeysPooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.The Endocannabinoid System as Pharmacological Target Derived from Its CNS Role in Energy Homeostasis and Reward. Applications in Eating Disorders and Addiction.Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.
P2860
Q24202931-6A56983D-AF75-47B7-9A6B-ECD86E77C26FQ24202961-53CC9CBD-287D-4447-8ED6-FE939A98CEB7Q28564481-76E9D57E-6ADF-4426-89C9-71542234116FQ34282073-569260F6-076C-44B9-ACF2-9C1C2AFD9397Q34320289-E8FE5B0C-0FAE-4E0D-8BA2-DEC561846450Q36087096-BC88E168-34E4-482D-8E2F-766C9768E627Q36184904-9FA91261-3E4C-4340-8190-32B3D0C822EBQ36275995-4F3B3E6A-B739-4E1C-BBAB-0BB3E6FD0817Q37619820-81BAAADC-6CB4-449B-8C98-13BC03F232A4Q37728629-94F83CED-7E5B-45B0-B564-3E61D87B97BBQ40446321-39ED0107-7637-4D66-9212-F9F9C54C46F3Q41873288-45AE252E-57DC-4728-A862-6A3BB6D48739Q46111417-317BE7F6-1335-4CBF-BF4C-AB0DA2F24978Q50226059-68C28BA5-9B3E-4DD5-A6D6-581846043FB3Q53282635-AB8B5275-C951-4A62-9085-5AF00B99E2D1
P2860
Cannabinoid type 1 receptor antagonists for smoking cessation
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cannabinoid type 1 receptor antagonists for smoking cessation
@ast
Cannabinoid type 1 receptor antagonists for smoking cessation
@en
Cannabinoid type 1 receptor antagonists for smoking cessation
@en-gb
Cannabinoid type 1 receptor antagonists for smoking cessation
@nl
type
label
Cannabinoid type 1 receptor antagonists for smoking cessation
@ast
Cannabinoid type 1 receptor antagonists for smoking cessation
@en
Cannabinoid type 1 receptor antagonists for smoking cessation
@en-gb
Cannabinoid type 1 receptor antagonists for smoking cessation
@nl
prefLabel
Cannabinoid type 1 receptor antagonists for smoking cessation
@ast
Cannabinoid type 1 receptor antagonists for smoking cessation
@en
Cannabinoid type 1 receptor antagonists for smoking cessation
@en-gb
Cannabinoid type 1 receptor antagonists for smoking cessation
@nl
P2860
P921
P3181
P1476
Cannabinoid type 1 receptor antagonists for smoking cessation
@en
P2093
Kate Cahill
Michael H Ussher
P2860
P304
P3181
P356
10.1002/14651858.CD005353.PUB4
P577
2011-03-16T00:00:00Z